This was investigated in vivo using a mouse air-pouch model of inflammation.
In vivo studies involved the anti-inflammatory effect of birch extracts on TPA-induced model of inflammation in mice.
These highly selective IRAK4 compounds show activity in vivo via oral dosing in a TLR7 driven model of inflammation.
Finally, the biological evaluation of [18F]EFB in P2X7-transfected cells and in an intraperitoneal lipopolysaccharide (LPS) preclinical model of inflammation is presented.
Accordingly, the activation of CB2 receptors reduces spinal fos protein expression and pain behaviour in a rat model of inflammation [42].
The anti-inflammatory properties of these compounds were evaluated in an in vitro model of inflammation [cells exposed to 0.1 μg/ml lipopolysaccharide (LPS) for 24 h].
Using a tissue cage model of inflammation, the pharmacokinetic properties of marbofloxacin were established for serum, inflamed tissue cage fluid (exudate) and non-inflamed tissue cage fluid (transudate).
Both compounds exhibit anti-inflammatory effect in the dorsal air pouch model of inflammation as shows by inhibition of PGE2 secretion.
Triazole derivative 13 was found to have moderate bioavailability in the rat and demonstrated potent in-vivo activity in an acute model of inflammation.
Furthermore, compound IIj blocked mice ear inflammation by 75% and attenuated ear edema and damage substantially in an in vivo model of inflammation.
The starting point is a very simplistic, generic model of inflammation, which has been shown to capture the principles of infection, trauma, and sepsis surprisingly well.
